
Zhongwen Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5012760/publications.pdf Version: 2024-02-01



7HONOWEN LI

#	Article	IF	CITATIONS
1	Stem cell therapy for COVIDâ€19, ARDS and pulmonary fibrosis. Cell Proliferation, 2020, 53, e12939.	5.3	71
2	Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis. Cell Research, 2020, 30, 794-809.	12.0	57
3	A fully defined static suspension culture system for large-scale human embryonic stem cell production. Cell Death and Disease, 2018, 9, 892.	6.3	23
4	Phase 1 trial for treatment of COVIDâ€19 patients with pulmonary fibrosis using hESCâ€IMRCs. Cell Proliferation, 2020, 53, e12944.	5.3	19
5	Hyaluronate supports hESCâ€cardiomyocyte cell therapy for cardiac regeneration after acute myocardial infarction. Cell Proliferation, 2020, 53, e12942.	5.3	11
6	Discovery and structure-activity relationship study of phthalimide-phenylpyridine conjugate as inhibitor of Wnt pathway. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 870-872.	2.2	7
7	First case of COVIDâ€19 infused with hESC derived immunity―and matrixâ€regulatory cells. Cell Proliferation, 2020, 53, e12943.	5.3	7
8	Synthesis and anti-tumor activity evaluation of salinomycin C20- <i>O</i> -alkyl/benzyl oxime derivatives. Organic and Biomolecular Chemistry, 2022, 20, 870-876.	2.8	5
9	Regulations in the United States for Cell Transplantation Clinical Trials in Neurological Diseases. Translational Neuroscience and Clinics, 2015, 1, 114-124.	0.1	1
10	The Structureâ€Activity Relationship Study of Dicarboximideâ€phenylpyridine Conjugates as Inhibitors of Wnt Signaling Pathway. ChemistrySelect, 2020, 5, 13795-13799.	1.5	0